Evidence map›Paper›PMID 34031658›Full record

ArticlebioRxiv : the preprint server for biology2021

4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replication.

Julien Sourimant, Carolin M Lieber, Megha Aggarwal, Robert M Cox, Josef D Wolf, Jeong-Joong Yoon, Mart Toots, Chengin Ye, Zachary Sticher, Alexander A Kolykhalov and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Julien Sourimant
Carolin M Lieber
Megha Aggarwal
Robert M Cox
Josef D Wolf
Jeong-Joong Yoon
Mart Toots
Chengin Ye
Zachary Sticher
Alexander A Kolykhalov
Luis Martinez-Sobrido
Gregory R Bluemling
Michael G Natchus
George R Painter
Richard K Plemper

Funding

Identification and Pre-Clinical Evaluation of Measles Virus InhibitorsR01AI071002 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2006 to 2022
$6.6M
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza VirusesR01AI141222 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2019 to 2023
$5.0M
Polymerase Inhibitors of Respiratory Syncytial VirusR01AI153400 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2020 to 2024
$3.7M
NIAID NIH HHS R01 AI071002NIAID NIH HHS R01 AI141222NIAID NIH HHS R01 AI153400
6 · The paper itself

Abstract

The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4'-fluorouridine (4'-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and SARS-CoV-2 with high selectivity index in cells and well-differentiated human airway epithelia. Polymerase inhibition in ONE-SENTENCE SUMMARY: 4'-Fluorouridine is an orally available ribonucleoside analog that efficiently treats RSV and SARS-CoV-2 infections

Identifiers

PMID34031658
PMCPMC8142655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.